Below is a chart of Amgen (AMGN) from 1993 to 2021, reflecting Price Momentum data.
- Japan
- Market Indicator
- Price Momentum Indicators
- Richard Russell
- Silver
- Speed Resistance Lines
- U.S. Dividend Watch List
Below is a chart of Amgen (AMGN) from 1993 to 2021, reflecting Price Momentum data.
| Symbol | Name | Price | P/E | EPS | Yield | P/B | % from Low |
| CSCO | Cisco Systems, Inc. | $18.85 | 14.26 | $1.32 | 0 | 2.26 | 1.56% |
| AMGN | Amgen Inc. | $52.24 | 10.91 | $4.79 | 0 | 2.04 | 3.94% |
| CEPH | Cephalon, Inc. | $58.63 | 11.13 | $5.27 | 0 | 1.68 | 6.60% |
| TEVA | Teva Pharma. | $51.89 | 14.16 | $3.66 | 1.70% | 2.13 | 10.43% |
| ATVI | Activision Blizzard, Inc | $11.07 | 33.55 | $0.33 | 1.50% | 1.3 | 10.81% |
| CELG | Celgene Corp. | $53.47 | 28.44 | $1.88 | 0 | 4.79 | 11.35% |
| EXPE | Expedia, Inc. | $20.96 | 14.36 | $1.46 | 1.30% | 2.15 | 14.54% |
| MSFT | Microsoft Corp. | $27.06 | 11.55 | $2.34 | 2.40% | 4.72 | 19.05% |
| MICC | Millicom Intl. Cellular | $90.27 | 5.92 | $15.24 | 2.60% | 3.06 | 19.86% |
Watch List Performance Review
| Symbol | Name | 2010 | 2011 | Change |
| APOL | Apollo Group | $56.92 | $45.82 | -19.50% |
| ERTS | Electronic Arts | $16.75 | $19.28 | 15.10% |
| FSLR | First Solar | $116.00 | $168.22 | 45.02% |
| ATVI | Activision | $10.79 | $11.07 | 2.59% |
| PPDI | Pharma Prod. | $21.20 | $27.97 | 31.93% |
| SRCL | Stericycle | $54.30 | $87.38 | 60.92% |
| GENZ | Genzyme | $55.97 | $75.38 | 34.68% |
| GILD | Gilead | $48.84 | $39.30 | -19.53% |
| Average | 18.90% | |||
| NDX | Nasdaq 100 | 1823.32 | 2392.47 | 31.22% |
| Symbol | Name | Price | P/E | EPS | Yield | P/B | % from Low |
| ISRG | Intuitive Surgical | $267.40 | 31.8 | $8.40 | - | 5.26 | 8.68% |
| CEPH | Cephalon, Inc. | $60.32 | 11.3 | $5.35 | - | 1.81 | 9.67% |
| CSCO | Cisco Systems | $20.97 | 15.4 | $1.36 | - | 2.62 | 10.37% |
| APOL | Apollo Group, Inc. | $37.98 | 10.5 | $3.62 | - | 4.30 | 12.54% |
| AMGN | Amgen Inc. | $56.98 | 12.3 | $4.63 | - | 2.24 | 13.37% |
| ERTS | Electronic Arts | $16.05 | - | -$0.48 | - | 2.04 | 14.17% |
| QGEN | Qiagen N.V. | $19.32 | 30.4 | $0.64 | - | 1.89 | 14.59% |
| TEVA | Teva Pharma. | $54.01 | 16.6 | $3.25 | 1.30% | 2.22 | 14.94% |
| VRTX | Vertex Pharma. | $36.16 | - | -$3.73 | - | 11.31 | 15.71% |
| GRMN | Garmin Ltd. | $30.53 | 8.3 | $3.66 | 4.80% | 2.10 | 16.93% |
| INTC | Intel Corporation | $20.66 | 11.2 | $1.85 | 3.00% | 2.43 | 17.39% |
| GILD | Gilead Sciences | $37.50 | 11.0 | $3.42 | - | 5.36 | 18.18% |
| SHLD | Sears Holdings | $70.18 | 41.9 | $1.68 | - | 0.94 | 18.53% |
| ^NDX | Nasdaq 100 | 2,276.70 | |||||
| Symbol | Name | 2010 | 2011 | % change |
| GILD | Gilead Sciences | 44.54 | 37.50 | -15.81% |
| CEPH | Cephalon, Inc. | 63.01 | 60.32 | -4.27% |
| GENZ | Genzyme Corp | 53.81 | 71.39 | 32.67% |
| APOL | Apollo Group | 60.50 | 37.98 | -37.22% |
| Average | -6.16% | |||
| ^NDX | Nasdaq 100 | 1892.59 | 2276.70 | 20.30% |
One way that the New Low Observer (NLO) has managed to isolate whether a stock is at a low price is by waiting until the stock is within 20% of the new low. This approach isn't a cure for what ails the average investor. However, it does allow average market participants the opportunity to investigate quality companies for potential price increases. The new low of a stock automatically implies that value has been created especially if the company in question can survive as a going concern. This is counter to most information coming out of the Wall Street media machine. Typically, analysts on Wall Street recommend stocks that have risen far above the low before initiating coverage on a stock.
While there are 4336 individual stocks that can be bought on American stock exchanges, NLO has determined that there are basically only 383 companies that warrant your attention. The first group of companies are known as the Dividend Achievers (excel list of companies). These 283 companies are tracked by Mergent's based on their ability to increase their dividends every year for over 10 years in a row as a minimum requirement. It goes without saying that these companies pay some kind of dividend with yields that range from over 5% to less than 1%.
The second major group of companies tracked by NLO are the constituents of the Nasdaq 100. In our earlier forms as Dividend Inc. and Arti Invest, we believed that only Dividend Achievers were worth tracking since the dividend payment was verifiable regardless of "accounting" inconsistencies that are commonly found with "other" companies. The performance of this approach has been well documented and proven quite profitable.
However, the reality of the stock market dictates that we widen our perspective on companies that might afford significant opportunity with reduced risk. We, at NLO, decided that the Nasdaq 100 was the next obvious choice. After all, most mutual funds are bound to invest in these companies regardless of their unwillingness to pay dividend income. Additionally, companies in the Nasdaq 100 have solid reputations with higher prospects for growth over the long term.
One recent example of the benefit of tracking and research companies posted on NLO, as opposed to those from the Wall Street media machine, is Stericycle (SRCL). SRCL last appeared on our Nasdaq 100 watch list on October 30th. After being on our watchlist since the July 24th initiation of our website, SRCL has managed to climb from the low of $47.76 to the most recent high of $58. This is an increase of 18% from the July low and 21% from the October low and 11.54% from the breakout above our watch list range of being within 20% of the 52-week low.
NLO can be easily contrasted with the recent short-term buy recommendation placed on SRCL by Zack's Investment Research. In a tiny blurb issued today, Zack's Investment Research indicated that SRCL's stock had been in an oversold state based on the stochastics which indicated or implied that the stock was likely to go higher in the near term.
SRCL is only one of the companies that has been on the NLO Nasdaq 100 Watchlist that performed exceptionally well after getting off the list. Below are other Nasdaq 100 companies and their performance since getting within 20% of the new low:
It should be noted that the above companies are almost the entire list of companies that have appeared on the Nasdaq 100 Watch List. So far, this implies that quality Nasdaq companies could be investigated for speculative opportunities near the new low. Hopefully this approach can provide a reasonable approach to buying low with the prospect of selling higher. Follow along with us as we continue to investigate the speculative opportunities of the Nasdaq 100. -Touc
The following are the Nasdaq 100 members that are within 20% of the 52-week low:
It is interesting to note the percentage change that has occurred in last week's Nasdaq 100 watch list. Last week's list had the following one week percentage change:
The biotech/pharma sector is moving higher. As we've stated before, these companies are very undervalued at the present time. Do your research and carefully consider the opportunities. Touc.
The following are the Nasdaq 100 members that are within 20% of the 52-week low:
The fact that all of these companies (except for APOL) are within the drug industry does not surprise me. The continued undervaluation of these companies makes them prime targets for acquisition by investors and larger drug companies. Touc.